HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the Company will deliver an oral presentation on its lead product candidate azeliragon at the 2016 Alzheimer’s Association International Conference (AAIC).
The oral presentation will take place in Toronto, Canada on Wednesday, July 27, 2016 at 5:15 p.m. EDT. A copy of the presentation will be made available in the News & Events section of the Company’s website following the presentation.
Azeliragon is a novel orally administered small molecule antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) being evaluated in a pivotal Phase 3 study (STEADFAST). Activation of RAGE is believed to contribute to Alzheimer’s disease by promoting an influx of amyloid beta into the brain, increasing hyperphosphorylation of tau and amyloid beta, and promoting vascular amyloid deposition and inflammation. Azelerigon is designed to inhibit RAGE, which affects amyloid beta accumulation, tau hyperphosphorylation and chronic inflammation, three of the principal causes of neuronal damage in Alzheimer’s disease.
Previous Phase 2b results of 5mg per day over a period of 18 months showed statistically significant efficacy compared to placebo in mild-to-moderate Alzheimer’s disease subjects (+3.1 points on ADAS-Cog11 standard measure of cognition). Efficacy was more pronounced in mild patients (+4.0 points on ADAS-Cog11) with statistically significant results in favor of treatment on secondary endpoints including the Clinical Dementia Rating Scale Sum of Boxes and reduction of psychiatric adverse events.
About the STEADFAST Trial
The Phase 3 STEADFAST trial is a randomized, double-blind, placebo-controlled study evaluating whether azeliragon can effectively slow the cognitive and functional decline of patients with mild Alzheimer’s disease (AD). The Company anticipates enrolling 800 patients in the United States and Canada who will receive 18 months of treatment, and expects to report topline data for Part A of the study in late 2017/early 2018. The STEADFAST trial is being conducted under a Special Protocol Assessment (SPA) and the azeliragon development program has been granted Fast Track Designation from the FDA.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.